Trade Reata Pharma - RETA CFD

Add to favourite

172.23

0.03%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data

Trading сonditions

Spread

0.29

Long position overnight fee

-0.023346%

Short position overnight fee

0.001124%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	172.17
Open	172.23
1-Year Change	680.38%
Day's Range	172.19 - 172.24

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Sep 25, 2023	172.23	0.02	0.01%	172.21	172.32	172.18
Sep 22, 2023	172.17	0.00	0.00%	172.17	172.19	172.11
Sep 21, 2023	172.02	-0.08	-0.05%	172.10	172.21	171.98
Sep 20, 2023	172.07	0.10	0.06%	171.97	172.07	171.97
Sep 19, 2023	171.97	0.14	0.08%	171.83	172.00	171.83
Sep 18, 2023	171.90	0.08	0.05%	171.82	171.93	171.60
Sep 15, 2023	171.83	-0.08	-0.05%	171.91	172.00	171.69
Sep 14, 2023	171.92	0.05	0.03%	171.87	171.93	171.84
Sep 13, 2023	171.87	0.00	0.00%	171.87	171.94	171.81
Sep 12, 2023	171.83	1.44	0.85%	170.39	171.91	170.08
Sep 11, 2023	170.82	0.95	0.56%	169.87	170.97	169.87
Sep 8, 2023	170.15	0.58	0.34%	169.57	170.23	169.57
Sep 7, 2023	170.02	0.60	0.35%	169.42	170.11	169.42
Sep 6, 2023	169.51	0.34	0.20%	169.17	169.60	169.05
Sep 5, 2023	169.61	0.94	0.56%	168.67	169.83	168.67
Sep 1, 2023	169.13	0.31	0.18%	168.82	169.36	168.82
Aug 31, 2023	168.83	0.22	0.13%	168.61	169.11	168.61
Aug 30, 2023	168.53	-0.22	-0.13%	168.75	169.03	168.53
Aug 29, 2023	168.75	-0.07	-0.04%	168.82	168.94	168.66
Aug 28, 2023	168.77	-0.10	-0.06%	168.87	169.17	168.71

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Reata Pharma Company profile

About Reata Pharmaceuticals Inc

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on identifying, developing, and commercializing therapies. The Company is also focused on providing small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with therapies. The Company's lead programs are in rare forms of chronic kidney disease and rare neurological disease. The Company’s Bardoxolone methyl and omaveloxolone products are in development for the treatment of several forms of chronic kidney disease and a severe neurologic disorder called Friedreich’s ataxia, respectively. The Company’s Technologies include Nrf2 Activators and HSP90 Modulators. Nrf2 is a transcription factor that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. HSP90 Modulators developing a class of molecules that target pathways involved in the cellular stress response.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Reata Pharmaceuticals Inc revenues increased 27% to $11.5M. Net loss before extraordinary items increased 10% to $297.4M. Revenues reflect License and milestone increase of 71% to $8M. Higher net loss reflects Other Non Operating I/E increase from $21.9M to $46.7M (expense), General and administrative - Balancing increase of 44% to $65.8M (expense).

Industry:

Biopharmaceuticals

5320 Legacy Dr
PLANO
TEXAS 75024-3127
US